PLT 99257
Latest Information Update: 21 Nov 2006
At a glance
- Originator Pilot Therapeutics
- Class Antineoplastics; Retinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Nov 2006 Discontinued - Preclinical for Cancer in USA (PO)
- 22 Apr 2002 Preclinical trials in Cancer in USA (PO)